Testosterone for women: one proven use, zero approved products

What does testosterone do in a woman's body?

Testosterone is a sex hormone women produce in the ovaries and adrenal glands, circulating at concentrations roughly a tenth of a man's or lower: 15 to 46 ng/dL total testosterone covers the 5th to 95th percentile for a healthy 30-year-old woman (Braunstein 2011, PMID 21771278). It acts on androgen receptors in brain, bone, muscle and genital tissue, and the effect proven in randomized trials is on sexual desire, arousal and response after menopause. Testosterone is a normal female hormone rather than a male hormone women lack, and a woman's ovaries keep producing it after menopause even as estrogen falls.

No testosterone product is FDA-approved for women. Prescriptions are off-label fractions of male products or compounded preparations, and compounded preparations are not FDA-reviewed for potency or quality. Our compounded-vs-approved guide.

What is a normal testosterone level for a woman?

The reference study most often cited measured 161 healthy, normally cycling women aged 18 to 49and estimated percentiles for a 30-year-old woman. Its numbers, with the study's own basis attached:

From Braunstein GD et al., Testosterone reference ranges in normally cycling healthy premenopausal women, J Sex Med 2011, PMID 21771278. Two findings travel with the table: “Serum testosterone concentrations exhibited an age-related decline, whereas SHBG remained relatively stable across studied age ranges.” and the mid-cycle rise is small enough that “these reference ranges can be applied irrespective of the day in the menstrual cycle the sample has been taken”. Note what the ranges are and are not: percentiles of healthy women measured by immunoassay, which is a description of normal. Labs using different assays print different reference intervals, and mass spectrometry, the method the consensus statement prefers at these low concentrations, reads lower than many direct immunoassays. Your lab report's own interval is the one your result was measured against.

One more sentence belongs next to any lab slip. The consensus statement is blunt about what a level can and cannot do: “A blood total testosterone level should not be used to diagnose HSDD.” A testosterone number identifies excess and guides dosing once treatment starts. It does not diagnose low desire, and a clinic that diagnoses you from a number alone is skipping the assessment the evidence requires.

What are the symptoms of low testosterone in women?

Here is where this page diverges from most of what ranks for this query. Lists circulating online attribute fatigue, brain fog, low mood, weight gain and muscle loss to low testosterone in women. The panel that actually reviewed the trial evidence, across every one of those claims, concluded: “There are insufficient data to support the use of testosterone for the treatment of any other symptom or clinical condition, or for disease prevention.” On cognition specifically: “There is insufficient evidence to support the use of testosterone to enhance cognitive performance, or to delay cognitive decline, in postmenopausal women (Insufficient).”

What survives the evidence review is one condition: hypoactive sexual desire disorder, HSDD, a persistent and distressing loss of sexual desire. The consensus statement's full indication sentence: “The only evidence-based indication for the use of testosterone in women is for the treatment of postmenopausal women who have been diagnosed as having HSDD after formal biopsychosocial assessment (Level I, Grade A).” The words doing the work are postmenopausal and formal biopsychosocial assessment. The diagnosis is clinical: distress, duration, and the exclusion of the things that flatten desire on their own, including relationship strain, depression, and medications such as SSRIs.

Read the effect size honestly. One additional satisfying sexual event per month, with measurable movement across desire and arousal scales, is a real and moderate effect. It is also the entire proven benefit. The consensus panel put a time limit on what is known about safety: “Safety data for testosterone in physiologic doses are not available beyond 24 months of treatment (Level I, Grade A).”

If what brought you here is hot flashes, night sweats, sleep disruption or vaginal symptoms, testosterone is the wrong page. The 2022 Menopause Society position statement: “Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.”That is estrogen's territory, with progesterone alongside it if you have a uterus. Start at menopause symptoms and progesterone, and use the Menopause Rating Scale to put numbers on what you are feeling before any consult.

What does high testosterone mean in a woman?

The same lab test that runs low runs high, and high has a shorter, sharper differential. Sustained elevation with irregular cycles, acne or excess facial and body hair points most often toward polycystic ovary syndrome, and the workup for that belongs with a clinician following the international evidence-based PCOS guideline (Teede 2018, PMID 30052961). Rapid-onset virilization, meaning voice deepening, clitoral enlargement or male-pattern hair loss developing over months, is a different and urgent picture that needs prompt evaluation for an androgen-secreting tumor. PCOS care sits outside what the platforms we track offer, so this page links you to the guideline and stops there.

One external cause is documented on a drug label rather than in an endocrinology text. The AndroGel boxed warning exists because the hormone rubs off: “Virilization has been reported in children who were secondarily exposed to testosterone gel”, and the label instructs that “Children and women should avoid contact with unwashed or unclothed application site(s) of men using AndroGel 1.62%.” A woman with an unexplained testosterone rise who shares a bed with a gel user has a checkable first hypothesis. The same label is why off-label gel use by women demands care around children and pregnancy: “AndroGel 1.62% is contraindicated in women who are pregnant. AndroGel 1.62% can cause virilization of the female fetus when administered to a pregnant woman.”

Which forms of testosterone can women actually get?

Every route below is off-label for women, because every approved product is a male product. The AndroGel label states the indication: “AndroGel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone” and, in its use-in-women section, closes the question in one line: “AndroGel 1.62% is not indicated for use in women.” What distinguishes the routes is how precisely a female dose can be delivered and monitored.

The oral-route lipid finding, verbatim from the meta-analysis: “A significant rise in the amount of LDL-cholesterol, and reductions in the amounts of total cholesterol, HDL-cholesterol, and triglycerides, were seen with testosterone administered orally, but not when administered non-orally (eg, by transdermal patch or cream).”

The fractional-dose mechanics, with the label numbers

The arithmetic of off-label female dosing starts from the male label. AndroGel 1.62% starts men at 40.5 mg of testosterone daily, adjustable between 20.25 mg and 81 mg, titrated to hold blood levels between 350 and 750 ng/dL. A woman being treated to her own physiologic range, whose ceiling is 46 ng/dL in the reference data above, needs a small fraction of the smallest male dose. The consensus statement leaves the exact fraction to titration and states the rule instead: “Where an appropriate approved female testosterone preparation is not available, off-label, prescribing of an approved male formulation is reasonable, provided hormone concentrations are maintained in the physiologic female range (Expert Opinion).” The ISSWSH guideline turns that into practice: “Patients should be assessed for signs of androgen excess and total testosterone levels monitored to maintain concentrations in the physiologic premenopausal range.” In its protocol, a baseline total testosterone is drawn before starting and rechecked within the first several weeks of treatment, then periodically, and signs of androgen excess, meaning acne, unwanted hair growth or scalp hair loss, are checked at each review.

On compounded creams, both documents say the same thing at different lengths. The consensus statement: “Compounded “bioidentical” testosterone therapy cannot be recommended for the treatment of HSDD because of the lack of evidence for efficacy and safety, unless an authorized equivalent preparation is not available (Expert Opinion).” The ISSWSH guideline: “Compounded products cannot be recommended because of the lack of efficacy and safety data.”Since no approved female product exists in the US, that exception clause is doing real work: a clinician who prefers a precisely titrated compounded female cream over an eyeballed fraction of a male gel is inside the statement's own carve-out, provided the pharmacy meets quality standards and levels are monitored. Compounded remains unreviewed by the FDA for potency and quality, which is the trade. The compounded-vs-approved distinction in full.

Why is there no FDA-approved testosterone for women?

It was tried, seriously, twice. The closest attempt was Intrinsa, a testosterone patch developed by Procter and Gamble. A Federal Register notice published October 28, 2004 called an FDA advisory committee meeting for December 2, 2004 with this agenda: “The committee will discuss new drug application (NDA) 21-769, Testosterone Transdermal System (proposed tradename, Intrinsa) by Procter and Gamble, indicated for the treatment of hypoactive sexual desire disorder in surgically menopausal women receiving concomitant estrogen therapy.” The committee met, and no approval followed. Searched on August 26, 2026, NDA 021769 returns no products in Drugs@FDA. Europe approved the patch for a period; the United States never did.

The second attempt was LibiGel. A 2012 cardiovascular-safety study protocol published in American Heart Journal recorded the ambition: “LibiGel (Biosante Pharmaceuticals, Inc., Lincolnshire, IL), a low-dose testosterone gel, is under development for the treatment of hypoactive sexual desire disorder (HSDD) in oophorectomized women.” The program built a randomized safety study designed for regulatory approval, and no approved product ever emerged from it either. The efficacy results that ended the program were announced by the company and sit outside the sources this page cites, so the checkable facts are the ones here: the development program existed at phase III scale, and Drugs@FDA lists no approved LibiGel.

The result is a market with a shape worth staring at. Testosterone itself has carried FDA approval since 1953, per the AndroGel label's own masthead line, “Initial U.S. Approval: 1953”. Seventy-three years of approved male products, zero approved female ones, and a consensus panel of 11 societies writing, in 2019: “There is an unmet need for the provision and approval of testosterone treatments specific to women, formulated with the aim of approximating physiological testosterone concentrations for premenopausal women (Expert Opinion).” Until a company runs the trials the FDA asked for, every woman on this therapy is on a male product at a fraction dose or a compounded preparation, and every marketing page that implies otherwise is wrong on the public record.

Do testosterone supplements for women contain testosterone?

No, and the reason is statutory. Testosterone is a controlled substance. The AndroGel label: “AndroGel 1.62% contains testosterone, a Schedule III controlled substance in the Controlled Substances Act.” The codified list is 21 CFR 1308.13, whose paragraph (f) covers anabolic steroids. Anything that actually contains testosterone requires a prescription and a DEA registration to dispense. A bottle on a supplement shelf that contained it would be an unapproved controlled drug, so it does not.

What a “testosterone booster for women” actually contains is herbs, vitamins and minerals: typically some mix of fenugreek, ashwagandha, maca, zinc and vitamin D. Marketing implies these raise testosterone meaningfully; the trial evidence for that claim in women is thin to absent, and none of these ingredients is a hormone. The one genuine hormone sold over the counter in this aisle is DHEA, a testosterone precursor, which is why it shows up in both supplement stores and, at prescription strength as vaginal prasterone, on Drugs@FDA. Our supplements page grades what the popular menopause supplements actually contain.

The practical test is one sentence long. If a product were capable of doing what the trials show testosterone does, it would be a Schedule III drug and you could not buy it without a prescription. Anything you can buy without one is making its claims from outside the evidence this page has been quoting.

Related

• Menopause symptoms what estrogen loss actually causes, and which symptoms HRT treats
• Progesterone the other half of standard HRT, with the platforms that price it
• Bioidentical HRT, compounded vs FDA-approved the distinction this whole page turns on
• Hormone pellets the form the consensus statement recommends against, in full
• Winona review the women's wing score leader, compounded formulary included
• Testosterone cypionate and the TRT rankings for the men's side